Glenmark targets US revenue above $430m in FY27 as margins expand
Glenmark Pharmaceuticals expects its US business to grow 10–12% annually and exceed $430 million in FY27, supported by respiratory launches and the Monroe plant. The company retained its 21–22% full-year EBITDA-margin guidance after Q1 revenue rose 23.1% year on year.
Glenmark expects FY27 US revenue above $430 million and sustained 10–12% annual growth, supported by respiratory launches and its Monroe plant. It maintained 21–22% EBITDA-margin guidance while India revenue grew about 15.5%, led by chronic, cardiac, respiratory and oncology therapies.
Why this matters
The US expansion target follows Glenmark Consumer Care sales rising 28%, with Candid and Scalpe each growing more than 30%, indicating momentum across Glenmark's portfolio.
Retail-company signals are accelerating, up 207614% QoQ.